0JW9.LSE MEI Pharma Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -170.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 0JW9.LSE undervalued?
Graham numberThe Graham number of MEI Pharma Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MEI Pharma Inc. fundamental analysis
No fundamental analysis for MEI Pharma Inc. yet.
MEI Pharma Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MEI Pharma Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Full company profileMEI Pharma Inc. financial statements
MEI Pharma Inc. annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 23.2M | 1.62M | 4.92M | 28.9M | 34.8M | 40.7M | 48.8M | 65.3M | - | - |
| Gross Profit | 18.2M | -1.76M | 652K | 26.2M | 33.4M | 39.5M | 47.0M | 64.9M | -368K | - |
| Operating Income | 2.38M | -28.6M | -46.2M | -24.5M | -60.4M | -75.5M | -33.2M | 25.4M | -17.5M | -12.3M |
| EBITDA | 2.47M | -28.5M | -46.2M | -25.6M | -60.1M | -53.2M | -31.3M | 26.4M | -15.6M | -12.3M |
| Net Income | 2.67M | -40.1M | -16.8M | -46.0M | -41.3M | -54.5M | -31.8M | 17.8M | -15.9M | -71.2M |
| EPS | 1.45 | -19 | -4.65 | -10 | -7.22 | -8.70 | -4.78 | 2.67 | -2.39 | -2.06 |
| Balance Sheet | ||||||||||
| Total Assets | 55.7M | 105M | 82.7M | 210M | 174M | 178M | 121M | 41.4M | 18.3M | 42.7M |
| Total Liabilities | 4.87M | 54.2M | 34.7M | 132M | 125M | 125M | 96.2M | 8.36M | 1.35M | 1.07M |
| Shareholders' Equity | 50.8M | 50.5M | 47.9M | 78.2M | 49.5M | 52.4M | 24.6M | 33.0M | 16.9M | 41.6M |
| Cash & Short-term Investments | 53.6M | 103M | 74.5M | 183M | 153M | 153M | 101M | 38.3M | 18.0M | 5.71M |
| Total Debt | - | - | - | - | 8.30M | 9.64M | 12.7M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 3.49M | -21.3M | -29.4M | 34.3M | -32.0M | -48.7M | -52.5M | -50.5M | -20.8M | -9.12M |
| Capital Expenditure | 51.0K | 217K | 217K | 894K | 708K | 479K | 35.0K | 7.00K | 0.00 | 0.00 |
| Free Cash Flow | 3.44M | -21.3M | -29.6M | 33.4M | -32.7M | -49.2M | -52.5M | -50.5M | -20.8M | -9.12M |
| Ratios | ||||||||||
| ROE | 5.3% | -79.4% | -35.1% | -58.8% | -83.5% | -103.9% | -129.3% | 53.8% | -94.2% | -170.9% |
| ROA | 4.8% | -38.3% | -20.3% | -21.9% | -23.7% | -30.6% | -26.4% | 43.0% | -87.2% | -166.7% |
| Net Profit Margin | 11.5% | -2,470.3% | -342.2% | -159.2% | -118.7% | -133.8% | -65.2% | 27.2% | - | - |
| Debt to Equity | - | - | - | - | 0.17x | 0.18x | 0.52x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MEI Pharma Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | 11.7M | 1.75 | 65.6% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 0.05:1 on Apr 17, 2023.
Who owns MEI Pharma Inc.
- Insiders 1.38%
- Institutions 19.37%
- Public & others 79.26%
- Free float 28.2M
MEI Pharma Inc. company profile
- Company name
- MEI Pharma Inc.
- Ticker
- 0JW9.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 5
- Fiscal year end
- June
- Address
- 9920 Pacific Heights Blvd., San Diego, CA, United States, 92121
- Phone
- 858 369 7100
- Website
- litestrategy.com
About MEI Pharma Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
MEI Pharma Inc. management
3- Mr. Justin J. File CPACEO, CFO, Corporate Secretary & Director · born 1970
- Ms. Anne FreseChief People Officer
- Dr. Robert D. Mass M.D.Strategic Advisor · born 1954